Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | BCR | P11274 | 1/20 | 0.30 |
| ▸ | MARK3 | P27448 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675820 | 0.99 | KMT2A (0.32) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1559101 | 0.89 | PLK1 (0.33) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1203370 | 0.89 | KDM4E (0.32) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL4102107 | 0.88 | MARK3 (0.32) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1675579 | 0.88 | KMT2A (0.33) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL3990067 | 0.87 | HSD11B1 (0.32) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1560603 | 0.87 | KDM4E (0.32) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL1675604 | 0.86 | PLK1 (0.34) | PLK1 | |
| SCHEMBL2298460 | 0.85 | KDM4E (0.33) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL4109249 | 0.85 | CCNE1 (0.31) | KMT2AKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2205241-A1 | POLO-LIKE KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | KMT2A 1796/4885KDM4E 2195/4885MEN1 3731/4885 |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | KMT2A 1796/4885KDM4E 2195/4885MEN1 3731/4885 |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | KMT2A 1796/4885KDM4E 2195/4885MEN1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.